ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) vs placebo
Tardive dyskinesia: No clinically important improvement · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…
ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) probably leads to lower tardive dyskinesia: 1. No clinically important improvement compared with PLACEBO (moderate certainty).
1 finding from 1 review
- Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyRR 0.63 [0.46, 0.86]1 study · 92 participantsModerate